If you’re one of those owners or managers who’s thinking about registering for APC’s April 4-6 Owner Summit in La Jolla, Calif., you’d best think fast. The hotel room block at the Hilton La Jolla Torrey Pines is just about full.
Last week, Novo Nordisk reached confidential settlements in its trademark infringement lawsuits with a med spa and a weight loss clinic in Florida.
APC has partnered with the Pharmacy Compounding Foundation and the VCU School of Pharmacy to offer a 15-hour online CE program called “The Ethical Legal & Regulatory Foundations of Pharmacy Compounding."
We’ve heard from a few APC members who received communication recently from an entity claiming to represent a 503B outsourcing facility marketing sterile products to 503A compounding pharmacies.
A single meeting is seldom a touchdown. But this past Monday I joined an APC work group in a presentation that definitely moved the ball down the field in terms of expanded patient access to compounded therapies.
Last week, a Florida District Court judge denied Brooksville Pharmacy’s motion to dismiss Novo Nordisk’s amended lawsuit alleging potency discrepancies in the pharmacy’s compounded semaglutide.
It may seem early, but now is the time to get started on your application for the APC Fellows Program.
This week, APC submitted letters to two state legislatures—a joint letter with NCPA to Hawaii and a letter to Mississippi.
If you own or manage a compounding pharmacy, here are 10 questions to think about.
FDA recently released this year’s CDER Guidance Agenda, a list of new, revised draft, and immediately-in-effect guidance documents it plans to publish this year. There are five listed in the compounding category.
FOLLOW US
